Your browser doesn't support javascript.
loading
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia.
Fonseca, Paula Jiménez; Carmona-Bayonas, Alberto; García, Ignacio Matos; Marcos, Rosana; Castañón, Eduardo; Antonio, Maite; Font, Carme; Biosca, Mercè; Blasco, Ana; Lozano, Rebeca; Ramchandani, Avinash; Beato, Carmen; de Castro, Eva Martínez; Espinosa, Javier; Martínez-García, Jerónimo; Ghanem, Ismael; Cubero, Jorge Hernando; Manrique, Isabel Aragón; Navalón, Francisco García; Sevillano, Elena; Manzano, Aránzazu; Virizuela, Juan; Garrido, Marcelo; Mondéjar, Rebeca; Arcusa, María Ángeles; Bonilla, Yaiza; Pérez, Quionia; Gallardo, Elena; Del Carmen Soriano, Maria; Cardona, Mercè; Lasheras, Fernando Sánchez; Cruz, Juan Jesús; Ayala, Francisco.
Afiliação
  • Fonseca PJ; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez s/n, Murcia 30008, Spain.
  • García IM; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Marcos R; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Castañón E; Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Antonio M; Medical Oncology Department, ICO Duran i Reynals, Barcelona, Spain.
  • Font C; Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Biosca M; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Blasco A; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
  • Lozano R; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Ramchandani A; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain.
  • Beato C; Medical Oncology Department, Hospital NISA Aljarafe, Sevilla, Spain.
  • de Castro EM; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Espinosa J; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
  • Martínez-García J; Medical Oncology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Ghanem I; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
  • Cubero JH; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Manrique IA; Medical Oncology Department, Hospital Juan Ramón Jiménez, Huelva, Spain.
  • Navalón FG; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
  • Sevillano E; Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Manzano A; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Virizuela J; Medical Oncology Department, Hospital Universitario Virgen de Macarena, Sevilla, Spain.
  • Garrido M; Medical Oncology Department, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile.
  • Mondéjar R; Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.
  • Arcusa MÁ; Medical Oncology Department, Consorci Sanitari de Terrassa, Barcelona, Spain.
  • Bonilla Y; Intensive Care Unit, Hospital General Universitario Santa Lucía, Cartagena, Spain.
  • Pérez Q; Medical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Gallardo E; Medical Oncology Department, Complejo Universitario de Pontevedra, Pontevedra, Spain.
  • Del Carmen Soriano M; Medical Oncology Department, Hospital Virgen de la Luz de Cuenca, Madrid, Spain.
  • Cardona M; Internal Medicine Department, Hospital de Tortosa Verge de la Cinta, Tarragona, Spain.
  • Lasheras FS; Department of Construction and Manufacturing Engineering, University of Oviedo, Spain.
  • Cruz JJ; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Ayala F; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez s/n, Murcia 30008, Spain.
Br J Cancer ; 114(11): 1191-8, 2016 May 24.
Article em En | MEDLINE | ID: mdl-27187687
BACKGROUND: We sought to develop and externally validate a nomogram and web-based calculator to individually predict the development of serious complications in seemingly stable adult patients with solid tumours and episodes of febrile neutropenia (FN). PATIENTS AND METHODS: The data from the FINITE study (n=1133) and University of Salamanca Hospital (USH) FN registry (n=296) were used to develop and validate this tool. The main eligibility criterion was the presence of apparent clinical stability, defined as events without acute organ dysfunction, abnormal vital signs, or major infections. Discriminatory ability was measured as the concordance index and stratification into risk groups. RESULTS: The rate of infection-related complications in the FINITE and USH series was 13.4% and 18.6%, respectively. The nomogram used the following covariates: Eastern Cooperative Group (ECOG) Performance Status ⩾2, chronic obstructive pulmonary disease, chronic cardiovascular disease, mucositis of grade ⩾2 (National Cancer Institute Common Toxicity Criteria), monocytes <200/mm(3), and stress-induced hyperglycaemia. The nomogram predictions appeared to be well calibrated in both data sets (Hosmer-Lemeshow test, P>0.1). The concordance index was 0.855 and 0.831 in each series. Risk group stratification revealed a significant distinction in the proportion of complications. With a ⩾116-point cutoff, the nomogram yielded the following prognostic indices in the USH registry validation series: 66% sensitivity, 83% specificity, 3.88 positive likelihood ratio, 48% positive predictive value, and 91% negative predictive value. CONCLUSIONS: We have developed and externally validated a nomogram and web calculator to predict serious complications that can potentially impact decision-making in patients with seemingly stable FN.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Medição de Risco / Doença Pulmonar Obstrutiva Crônica / Nomogramas / Mucosite / Neutropenia Febril / Hiperglicemia / Infecções / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Medição de Risco / Doença Pulmonar Obstrutiva Crônica / Nomogramas / Mucosite / Neutropenia Febril / Hiperglicemia / Infecções / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha